Neuroendocrine differentiation of metastasised castrate-resistant prostate cancer patients referred for radioligand therapy with Lu-177 PSMA

#3292

Introduction: Neuroendocrine differentiation (NED) of metastasised castrate-resistant prostate cancer (mCRPC) is normally associated with poor prognosis.

Aim(s): This study aimed to find the predictive and prognostic value of NED biomarkers chromogranin A (CgA) and neuron specific enolase (NSE) in mCRPC after Lu-177 PSMA (RLT) therapy.

Materials and methods: 28 mCRPC patients (69±9y) undergoing RLT were analysed. Baseline PSA, CgA, NSE, LDH and AP were recorded from the clinical record. PSA response and PSMA-PET/CT (PET) based response assessment was performed at 4 and 6 weeks after the 2nd RLT respectively. >50% decrease in PSA was defined as partial response (PR), >25% increase was defined as progressive disease (PD) and PSA change between +25% and -50% were taken as stable disease (SD).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Prasad V

Authors: Grunert M, Miksch J, Steinacker J, Zengerling F, Glatting G,

Keywords: NED, mCRPC, CgA, NSE, RLT, overall survival,